Changes of osteopontin in the aqueous humor of the DBA2/J glaucoma model correlated with optic nerve and RGC degenerations

Investigative Ophthalmology and Visual Science

Volumn 51, Issue 11, 2010, Pages 5759-5767

  Birke, Marco T ^a   Neumann, Carolin ^a   Birke, Kerstin ^a   Kremers, Jan ^b,c   Scholz, Michael ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^c UNIVERSITY OF BRADFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

OSTEOPONTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AQUEOUS HUMOR; ARTICLE; CELL DEGENERATION; CELL SURVIVAL; CELLULAR DISTRIBUTION; CILIARY BODY; CONTROLLED STUDY; DBA 2 MOUSE; GLAUCOMA; IN SITU HYBRIDIZATION; INTRAOCULAR PRESSURE; MOUSE; NERVE DEGENERATION; NEURAL STEM CELL; NONHUMAN; OPTIC NERVE; OPTIC NERVE DISEASE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RETINA GANGLION CELL; WESTERN BLOTTING;

AGING; ANIMALS; AQUEOUS HUMOR; BLOTTING, WESTERN; CELL SURVIVAL; CYTOKINES; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; GLAUCOMA; IN SITU HYBRIDIZATION; INTRAOCULAR PRESSURE; MICE; MICE, INBRED C57BL; MICE, INBRED DBA; NERVE DEGENERATION; OPTIC NERVE DISEASES; ORGAN CULTURE TECHNIQUES; OSTEOPONTIN; RETINAL GANGLION CELLS; RNA, MESSENGER;

EID: 77956316327     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.10-5558     Document Type: Article

References (61)

1. Jakobs TC, Libby RT, Ben Y, John SWM, Masland RH. Retinal ganglion cell degeneration is topological but not cell type specific in DBA/2J mice. J Cell Biol. 2005;171:313-325.
2. Anderson MG, Libby RT, Mao M, et al. Genetic context determines susceptibility to intraocular pressure elevation in a mouse pigmentary glaucoma. BMC Biol. 2006;4:20.
3. Inman DM, Sappington RM, Horner PJ, Calkins DJ. Quantitative correlation of optic nerve pathology with ocular pressure and corneal thickness in the DBA/2 mouse model of glaucoma. Invest Ophthalmol Vis Sci. 2006;47:986-996.
4. Libby RT, Gould DB, Anderson MG, John SW. Complex genetics of glaucoma susceptibility. Annu Rev Genomics Hum Genet. 2005; 6:15-44.
5. Howell GR, Libby RT, John SW. Mouse genetic models: an ideal system for understanding glaucomatous neurodegeneration and neuroprotection. Prog Brain Res. 2008;173:303-321.
6. Anderson MG, Smith RS, Savinova OV, et al. Genetic modification of glaucoma associated phenotypes between AKXD-28/Ty and DBA/2J mice. BMC Genet. 2001;2:1.
7. Anderson MG, Smith RS, Hawes NL, et al. Mutations in genes encoding melanosomal proteins cause pigmentary glaucoma in DBA/2J mice. Nat Genet. 2002;30:81-85.
8. Scholz M, Buder T, Seeber S, Adamek E, Becker CM, Lutjen-Drecoll E. Dependency of intraocular pressure elevation and glaucomatous changes in DBA/2J and DBA/2J-Rj mice. Invest Ophthalmol Vis Sci. 2008;49:613-621.
9. Harazny J, Scholz M, Buder T, Lausen B, Kremers J. Electrophysiological deficits in the retina of the DBA/2J mouse. Doc Ophthalmol. 2009;119:181-197.
10. Gottanka J, Johnson DH, Martus P, Lutjen-Drecoll E. Severity of optic nerve damage in eyes with POAG is correlated with changes in the trabecular meshwork. J Glaucoma. 1997;6:123-132.
11. Gottanka J, Kuhlmann A, Scholz M, Johnson DH, Lutjen-Drecoll E. Pathophysiologic changes in the optic nerves of eyes with primary open angle and pseudoexfoliation glaucoma. Invest Ophthalmol Vis Sci. 2005;46:4170-4181.
12. Cumurcu T, Bulut Y, Demir HD, Yenisehirli G. Aqueous humor erythropoietin levels in patients with primary open-angle glaucoma. J Glaucoma. 2007;16:645-648.
13. Dan J, Belyea D, Gertner G, Leshem I, Lusky M, Miskin R. Plasminogen activator inhibitor-1 in the aqueous humor of patients with and without glaucoma. Arch Ophthalmol. 2005;123:220-224.
14. Doganay S, Evereklioglu C, Turkoz Y, Er H. Decreased nitric oxide production in primary open-angle glaucoma. Eur J Ophthalmol. 2002;12:44-48.
15. Evereklioglu C, Doganay S, Er H, Yurekli M. Aqueous humor adrenomedullin levels differ in patients with different types of glaucoma. Jpn J Ophthalmol. 2002;46:203-208.
16. Grus FH, Joachim SC, Sandmann S, et al. Transthyretin and complex protein pattern in aqueous humor of patients with primary open-angle glaucoma. Mol Vis. 2008;14:1437-1445.
17. Hu DN, Ritch R. Hepatocyte growth factor is increased in the aqueous humor of glaucomatous eyes. J Glaucoma. 2001;10:152-157.
18. Hu DN, Ritch R, Liebmann J, Liu Y, Cheng B, Hu MS. Vascular endothelial growth factor is increased in aqueous humor of glaucomatous eyes. J Glaucoma. 2002;11:406-410.
19. Knepper PA, Mayanil CS, Goossens W, et al. Aqueous humor in primary open-angle glaucoma contains an increased level of CD44S. Invest Ophthalmol Vis Sci. 2002;43:133-139.
20. Nolan MJ, Giovingo MC, Miller AM, et al. Aqueous humor sCD44 concentration and visual field loss in primary open-angle glaucoma. J Glaucoma. 2007;16:419-429.
21. Koliakos GG, Schlotzer-Schrehardt U, Konstas AG, Bufidis T, Georgiadis N, Dimitriadou A. Transforming and insulin-like growth factors in the aqueous humour of patients with exfoliation syndrome. Graefes Arch Clin Exp Ophthalmol. 2001;239:482-487.
22. Kuchtey J, Kallberg ME, Gelatt KN, Rinkoski T, Komaromy AM, Kuchtey RW. Angiopoietin-like 7 secretion is induced by glaucoma stimuli and its concentration is elevated in glaucomatous aqueous humor. Invest Ophthalmol Vis Sci. 2008;49:3438-3448.
23. MacKay EO, Kallberg ME, Barrie KP, et al. Myocilin protein levels in the aqueous humor of the glaucomas in selected canine breeds. Vet Ophthalmol. 2008;11:234-241.
24. Navajas EV, Martins JR, Melo LA Jr, et al. Concentration of hyaluronic acid in primary open-angle glaucoma aqueous humor. Exp Eye Res. 2005;80:853-857.
25. Roedl JB, Bleich S, Reulbach U, et al. Homocysteine levels in aqueous humor and plasma of patients with primary open-angle glaucoma. J Neural Transm. 2007;114:445-450.
26. Gonzalez-Avila G, Ginebra M, Hayakawa T, Vadillo-Ortega F, Teran L, Selman M. Collagen metabolism in human aqueous humor from primary open-angle glaucoma: decreased degradation and increased biosynthesis play a role in its pathogenesis. Arch Ophthalmol. 1995;113:1319-1323.
27. Kee C, Son S, Ahn BH. The relationship between gelatinase A activity in aqueous humor and glaucoma. J Glaucoma. 1999;8: 51-55.
28. Schlotzer-Schrehardt U, Lommatzsch J, Kuchle M, Konstas AG, Naumann GO. Matrix metalloproteinases and their inhibitors in aqueous humor of patients with pseudoexfoliation syndrome/ glaucoma and primary open-angle glaucoma. Invest Ophthalmol Vis Sci. 2003;44:1117-1125.
29. Tezel G, Kass MA, Kolker AE, Becker B, Wax MB. Plasma and aqueous humor endothelin levels in primary open-angle glaucoma. J Glaucoma. 1997;6:83-89.
30. Inatani M, Tanihara H, Katsuta H, Honjo M, Kido N, Honda Y. Transforming growth factor-beta 2 levels in aqueous humor of glaucomatous eyes. Graefes Arch Clin Exp Ophthalmol. 2001;239: 109-113.
31. Maier P, Broszinski A, Heizmann U, Boehringer D, Reinhard T. Determination of active TGF-beta2 in aqueous humor prior to and following cryopreservation. Mol Vis. 2006;12:1477-1482.
32. Min SH, Lee TI, Chung YS, Kim HK. Transforming growth factorbeta levels in human aqueous humor of glaucomatous, diabetic and uveitic eyes. Korean J Ophthalmol. 2006;20:162-165.
33. Ochiai Y, Ochiai H. Higher concentration of transforming growth factor-beta in aqueous humor of glaucomatous eyes and diabetic eyes. Jpn J Ophthalmol. 2002;46:249-253.
34. Ozcan AA, Ozdemir N, Canataroglu A. The aqueous levels of TGF-beta2 in patients with glaucoma. Int Ophthalmol. 2004;25: 19-22.
35. Picht G, Welge-Luessen U, Grehn F, Lutjen-Drecoll E. Transforming growth factor beta 2 levels in the aqueous humor in different types of glaucoma and the relation to filtering bleb development. Graefes Arch Clin Exp Ophthalmol. 2001;239:199-207.
36. Tripathi RC, Li J, Chan WF, Tripathi BJ. Aqueous humor in glaucomatous eyes contains an increased level of TGF-beta 2. Exp Eye Res. 1994;59:723-727.
37. Yamamoto N, Itonaga K, Marunouchi T, Majima K. Concentration of transforming growth factor beta2 in aqueous humor. Ophthalmic Res. 2005;37:29-33.
38. Yu XB, Sun XH, Dahan E, et al. Increased levels of transforming growth factor-betal and -beta2 in the aqueous humor of patients with neovascular glaucoma. Ophthalmic Surg Lasers Imaging. 2007;38:6-14.
39. Fuchshofer R, Birke M, Welge-Lussen U, Kook D, Lutjen-Drecoll E. Transforming growth factor-beta 2 modulated extracellular matrix component expression in cultured human optic nerve head astrocytes. Invest Ophthalmol Vis Sci. 2005;46:568-578.
40. Fuchshofer R, Welge-Lussen U, Lutjen-Drecoll E. The effect of TGF-beta2 on human trabecular meshwork extracellular proteolytic system. Exp Eye Res. 2003;77:757-765.
41. Neumann C, Yu A, Welge-Lussen U, Lutjen-Drecoll E, Birke M. The effect of TGF-beta2 on elastin, type VI collagen, and components of the proteolytic degradation system in human optic nerve astrocytes. Invest Ophthalmol Vis Sci. 2008;49:1464-1472.
42. Yu AL, Fuchshofer R, Birke M, et al. Hypoxia/reoxygenation and TGF-beta increase alphaB-crystallin expression in human optic nerve head astrocytes. Exp Eye Res. 2007;84:694-706.
43. Gottanka J, Chan D, Eichhorn M, Lutjen-Drecoll E, Ethier CR. Effects of TGF-beta2 in perfused human eyes. Invest Ophthalmol Vis Sci. 2004;45:153-158.
44. Bachmann B, Birke M, Kook D, Eichhorn M, Lutjen-Drecoll E. Ultrastructural and biochemical evaluation of the porcine anterior chamber perfusion model. Invest Ophthalmol Vis Sci. 2006;47: 2011-2020.
45. Goldblum D, Kontiola AI, Mittag T, Chen B, Danias J. Non-invasive determination of intraocular pressure in the rat eye: comparison of an electronic tonometer (TonoPen), and a rebound (impact probe) tonometer. Graefes Arch Clin Exp Ophthalmol. 2002;240:942-946.
46. Filippopoulos T, Danias J, Chen B, Podos SM, Mittag TW. Topographic and morphologic analyses of retinal ganglion cell loss in old DBA/2NNia mice. Invest Ophthalmol Vis Sci. 2006;47:1968-1974.
47. Filippopoulos T, Matsubara A, Danias J, et al. Predictability and limitations of non-invasive murine tonometry: comparison of two devices. Exp Eye Res. 2006;83:194-201.
48. Van Bergen NJ, Wood JP, Chidlow G, et al. Recharacterization of the RGC-5 retinal ganglion cell line. Invest Ophthalmol Vis Sci. 2009;50:4267-4272.
49. Krishnamoorthy RR, Agarwal P, Prasanna G, et al. Characterization of a transformed rat retinal ganglion cell line. Brain Res Mol Brain Res. 2001;86:1-12.
50. Comi C, Carecchio M, Chiocchetti A, et al. Osteopontin is increased in the cerebrospinal fluid of patients with alzheimer's disease and its levels correlate with cognitive decline. J Alzheimers Dis. 2010;19:1143-1148.
51. Iczkiewicz J, Jackson MJ, Smith LA, Rose S, Jenner P. Osteopontin expression in substantia nigra in MPTP-treated primates and in Parkinson's disease. Brain Res. 2006;1118:239-250.
52. Denhardt DT, Noda M, O'Regan AW, Pavlin D, Berman JS. Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival. J Clin Invest. 2001;107:1055-1061.
53. Jin JK, Na YJ, Moon C, et al. Increased expression of osteopontin in the brain with scrapie infection. Brain Res. 2006;1072:227-233.
54. McFarland HF, Martin R. Multiple sclerosis: a complicated picture of autoimmunity. Nat Immunol. 2007;8:913-919.
55. Schroeter M, Zickler P, Denhardt DT, Hartung HP, Jander S. Increased thalamic neurodegeneration following ischaemic cortical stroke in osteopontin-deficient mice. Brain. 2006;129:1426-1437.
56. Meller R, Stevens SL, Minami M, et al. Neuroprotection by osteopontin in stroke. J Cereb Blood Flow Metab. 2005;25:217-225.
57. Maetzler W, Berg D, Schalamberidze N, et al. Osteopontin is elevated in Parkinson's disease and its absence leads to reduced neurodegeneration in the MPTP model. Neurobiol Dis. 2007;25: 473-482.
58. Chidlow G, Wood JP, Manavis J, Osborne NN, Casson RJ. Expression of osteopontin in the rat retina: effects of excitotoxic and ischemic injuries. Invest Ophthalmol Vis Sci. 2008;49:762-771.
59. Satoh J, Obayashi S, Misawa T, et al. Neuromyelitis optica/Devic's disease: gene expression profiling of brain lesions. Neuropathology. 2008;28:561-576.
60. Wilhelm BT, Landry JR, Takei F, Mager DL. Transcriptional control of murine CD94 gene: differential usage of dual promoters by lymphoid cell types. J Immunol. 2003;171:4219-4226.
61. Mo JS, Anderson MG, Gregory M, et al. By altering ocular immune privilege, bone marrow-derived cells pathogenically contribute to DBA/2J pigmentary glaucoma. J Exp Med. 2003;197:1335-1344.